Evaluation of human peroxisome proliferator-activated receptor (PPAR) subtype selectivity of a variety of anti-inflammatory drugs based on a novel assay for PPARδ(β)

Journal of Pharmacological Sciences

Volumn 93, Issue 3, 2003, Pages 347-355

  Kojo, Hitoshi ^a,b   Fukagawa, Masao ^a   Tajima, Kaoru ^a   Suzuki, Akiko ^a   Fujimura, Takao ^a   Aramori, Ichiro ^a   Hayashi, Ken Ichi ^a   Nishimura, Shintaro ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b Biomarker Science Co Ltd   (Japan)

Author keywords

Coactivator; Leukotriene D4 antagonist; Non steroidal anti inflammatory drug; Peroxisome proliferator activated receptor; Subtype selectivity

Indexed keywords

2 [[[[2 (4 TERTBUTYL 1,3 THIAZOL 2 YL) 1 BENZOFURAN 5 YL]OXY]METHYL]PHENYL]ACETIC ACID; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; ARACHIDONIC ACID; AURANOFIN; BEZAFIBRATE; CARBACYCLIN; DICLOFENAC; FK 011; IBUPROFEN; INDOMETACIN; LEUKOTRIENE D4 ANTAGONIST; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENICILLAMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIROXICAM; PRANLUKAST; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR GAMMA; TIARAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOASSAY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FIBROBLAST CULTURE; MOLECULAR INTERACTION; MONKEY; NONHUMAN; RECEPTOR AFFINITY; RELIABILITY; SENSITIVITY AND SPECIFICITY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CERCOPITHECUS AETHIOPS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; PROTEIN SUBUNITS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0347447431     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.93.347     Document Type: Article

References (41)

1. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347:645-650.
2. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell. 1992;68:879-887.
3. Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, Rodan GA. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol Endocrinol. 1992;6:1634-1641.
4. Zhu Y, Alvares K, Huang Q, Rao MS, Reddy J. Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. J Biol Chem. 1993;268:26817-26820.
5. Chen F, Law SW, O'Malley BW. Identification of two mPPAR related receptors and evidence for the existence of five subfamily members. Biochem Biophys Res Commun. 1993;196:671-677.
6. Kliewer SA, Forman BM, Blumberg B, et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA. 1994;91:7355-7359.
7. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPARγ2: Tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994;8:1224-1234.
8. Elbrecht A, Chen Y, Cullinan CA, et al. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors γ1 and γ2. Biochem Biophys Res Commun. 1996;224:431-437.
9. Mukherjee B, Jow L, Croston GE, Paterniti JR Jr. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARγ2 versus PPARγ1 and activation with retinoiod X receptor agonists and antagonists. J Biol Chem. 1997;272:8071-8076.
10. Yu K, Bayona W, Kallen CB, et al. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem. 1995;270:23975-23983.
11. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sci USA. 1997;94:4312-4317.
12. Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc Natl Acad Sci USA. 1997;94:4318-4323.
13. 4 pathway to inflammation control. Nature. 1996;384:39-43.
14. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem. 1995;270:12953-12956.
15. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR γ2, a lipid-activated transcription factor. Cell. 1994;79:1147-1156.
16. Tai TAC, Jennermann C, Brown KK, et al. Activation of the nuclear receptor peroxisome proliferator-activated receptor γ promotes brown adipocyte differentiation. J Biol Chem. 1996;271:29909-29914.
17. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
18. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86.
19. Nagy L, Tontonoz P, Alvarez JGA, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell. 1998;93:229-240.
20. Tontonoz P, Nagy L, Alvarez JGA, Thomazy VA, Evans RM. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;83:241-252.
21. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-Δ12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell. 1995;83:803-812.
22. Krey G, Braissant O, L'Horset F, et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol. 1997;11:779-791.
23. Takada I, Yu RT, Xu HE, et al. Alteration of a single amino acid in peroxisome proliferator-activated receptor-α (PPARα) generates a PPARδ phenotype. Mol Endocrinol. 2000;14:733-740.
24. Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, Green S. The mouse perixosome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 1992;11:433-439.
25. Lucknow B, Schutz G. CAT constructions with multiple unique restriction sites for the functional analysis of eukaryotic promoters and regulatory elements. Nucleic Acids Res. 1987;15:5490.
26. Kwok RPS, Lundblad JR, Chrivia JC, et al. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature. 1994;370:223-226.
27. Onate SA, Tsai SY, Tsai M-J, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. 1995;270:1354-1357.
28. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997;272:3406-3410.
29. 2 synthases by ibuprofen, naproxen, and indomethacin. Biochem Pharmacol. 2001;62:1587-1595.
30. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature. 1998;393:790-793.
31. Obata T, Nambu F, Kitagawa T, et al. ONO-1078: An antagonist of leukotrienes. Adv Prostaglandin Thromboxane Leukot Res. 1987;17A:540-543.
32. Shi Y, Hon M, Evans RM. The peroxisome proliferator-activated receptor δ, an integrator of transcriptional repression and nuclear receptor signaling. Proc Natl Acad Sci USA. 2002;99:2613-2618.
33. Krogsdam A-M, Nielsen CAF, Neve S, et al. Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor δ-mediated transactivation. Biochem J. 2002;363:157-165.
34. Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor-κB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem. 1999;273:32833-32841.
35. Staels B, Koeng W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature. 1998;393:790-793.
36. Diep QN, Touyz RM, Schiffrin EL. Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase. Hypertension. 2000;36:851-855.
37. Elstner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA. 1998;95:8806-8811.
38. Chinetti G, Griglio S, Antonucci M, et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem. 1998;273:25573-25580.
39. Bishop-Bailey D, Hla T. Endothelial cell apoptosis induced by the perixosome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta 12,14-prostaglandin J2. J Biol Chem. 1999;274:17042-17048.
40. Heneka MT, Feinstein DL, Galea E, Gleichmann M, Wullner U, Klockgether T. Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. J Neuroimmunol. 1999;100:156-168.
41. Hatae T, Wada M, Yokoyama C, Shimonishi M, Tanabe T. Prostacyclin-dependent apoptosis mediated by PPARδ. J Biol Chem. 2001;276:46260-46267.